Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Anatara Lifesciences (ANR) has entered an immediate trading halt ahead of a capital raise
  • Anatara develops oral solutions for animals and humans with gastrointestinal issues such as IBS and inflammatory bowel disease
  • At this stage, it is uncertain what the funds will be used for, however, Anatara is preparing for IBS human clinical trial before the end of this year
  • The trial will test Anatara’s Gastrointestinal ReProgramming (GaRP) dietary supplement which has been shown to reduce gut inflammation, promote mucosal healing and reduce associated pains
  • Additionally, the company announced Non-Executive Director and former interim CEO, Dr Tracie Ramsdale, is retiring by rotation at the upcoming Annual General Meeting
  • Company shares last traded for 20 cents on Friday, October 9

Anatara Lifesciences (ANR) has entered an immediate trading halt ahead of a capital raise announcement.

The company will remain in the trading halt until Wednesday, October 21, unless details of the raise are announced earlier.

Anatara Lifesciences is a specialist life sciences company that develops evidence-based oral solutions for people and animals with gastrointestinal diseases such as irritable bowel syndrome (IBS) and inflammatory bowel disease.

While it is uncertain exactly what the funds will be put towards, Anatara is preparing for an IBS human clinical trial that will commence before the end of this year.

The trial will test Anatara’s Gastrointestinal ReProgramming (GaRP) dietary supplement, which has been shown to reduce gut inflammation, promote mucosal healing and reduce associated pains.

Additionally, Anatara hopes to soon form a partnership to commercialise its GaRP product.

Before Anatara entered a trading halt this morning, the company announced Non-Executive Director and former interim CEO, Dr Tracie Ramsdale, is retiring by rotation at the upcoming Annual General Meeting. The director isn’t seeking re-election.

“As a Non-Executive Director, Tracie was a member of Anatara’s audit and risk
management committee and the remuneration and nominations committee,” Chair Sue MacLeman said.

“Anatara thanks Tracie for her valuable contribution since joining the board on August 4, 2014,” Sue added.

Company shares last traded for 20 cents on Friday, October 9.

ANR by the numbers
More From The Market Herald

" Carnaby Resources (ASX:CNB) ends week in a trading halt

Carnaby Resources (ASX:CNB) enters a trading halt as it plans an upcoming capital raise.

" Askari Metals (ASX:AS2) plans to raise capital for lithium purchase

Askari Metals (AS2) has entered a trading halt as it plans an upcoming capital raise.
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals (ASX:TLX) planning capital raise

Telix Pharmaceuticals (ASX:TLX) enters a trading halt while it plans an upcoming capital raise.
Alice Queen (ASX:AQX) - Managing Director, Andrew Buxton

" Alice Queen (ASX:AQX) halts trade ahead of fresh capital

Mineral exploration company Alice Queen (ASX:AQX) has entered a trading halt ahead of a proposed capital…